Two neurosurgeons from the University of California San Francisco completed the first spine surgery with Carlsmed's aprevo, a patient-specific interbody for the treatment of adult spinal deformity.
Christopher Ames, MD, director of spinal tumor and spinal deformity surgery at UC San Francisco Medical Center, was assisted by Patrick Maloney, MD, in the procedure.
Aprevo is the only spine technology to receive the FDA's breakthrough device designation, according to the company.
The aprevo portfolio is designed to "eliminate the tedious and costly process of stock device inventory control and reprocessing," Carlsmed CEO Mike Cordonnier said in a Feb. 23 news release.